Determination of cisapride in human plasma by high-performance liquid chromatography
| Autor: | J. Honorato, Emilio García-Quetglas, B. Calahorra, J. J. Carballal, Miguel Angel Campanero |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Detection limit
Chromatography Calibration curve Organic Chemistry Clinical Biochemistry Ether Reversed-phase chromatography Biochemistry High-performance liquid chromatography Analytical Chemistry chemistry.chemical_compound chemistry Cisapride medicine Sample preparation Triethylamine medicine.drug |
| Zdroj: | Chromatographia. 47:537-541 |
| ISSN: | 1612-1112 0009-5893 |
| Popis: | An HPLC method has been developed for the quantification of cisapride in plasma for pharmacokinetic studies. Clebopride was used as internal standard. Plasma samples were extracted at alkaline pH withtert-butyl methyl ether. The organic phase was then extracted with sulphuric acid to eliminate endogenous interferences, and cisapride and the internal standard were then extracted at alkaline pH intotert-butyl methyl ether. After evaporation oftert-butyl methyl ether, the residue was analysed by HPLC. Chromatography was performed at 20°C on a 250mm×4mm i.d. reversed-phase column selective for basic compounds. The isocratic mobile phase was 48∶52 (v/v) acetonitrile-water containing 0.05 M potassium dihydrogen phosphate and 0.04 M triethylamine, adjusted to pH 5.5; the flow rate was 1 mL min−1. Cisapride and the internal standard were detected by ultraviolet monitoring at 276 nm. The calibration graph was linear for quantities of cisapride from 1 to 200 ng mL−1. Intra- and inter-day precision (CV) did not exceed 13.98%. The limit of quantitation (LOQ) was 0.68 ng mL−1 for human plasma. The applicability of the method has been demonstrated in a pharmacokinetic study of normal volunteers who received 10 mg cisapride orally. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink